Highly sulfated fucans for the treatment of fibrous adhesions
AssigneeARC Medical Devices Inc.
InventorsChristopher Michael Kevin Springate, Sailesh Haresh Daswani
Life of this patent
Estimating the term…
Abstract
A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
Claims17
A method of treating a fibrous adhesion in an animal comprising selecting a medically acceptable high-sulfate fucan composition to inhibit the fibrous adhesion and administering a therapeutically effective amount comprising a dosage range between 0.5 mg/kg and 50 mg/kg of the high-sulfate fucan to the site of a wound of the animal, wherein the medically acceptable high-sulfate fucan composition comprises a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
A method of treating a fibrous adhesion at a target site in an animal, comprising selecting an agent for treating a fibrous adhesion and administering a therapeutically effective amount between about 0.04 mg/kg and 25 mg/kg of the high-sulfate fucan to the animal, and wherein the administering comprises administering the therapeutically effective amount to the target site, wherein the agent comprises a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
A method for treating fibrous adhesions in a patient comprising administering a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
A method for treating a fibrous adhesion in a patient comprising identifying a selected target site in a patient comprising or susceptible to having the fibrous adhesion and then administering an agent for treating the fibrous adhesion wherein the agent comprises a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
A method for treating a fibrous adhesion in a patient comprising identifying a selected target site in a patient comprising or susceptible to having the fibrous adhesion and then administering the medical composition to the selected target site in the patient, wherein the medical composition is a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
Dependencies are inferred from the claim text.